To test whether CK2 inhibition impaired BCR signaling in DLBCLs, we chose three GCB-DLBCL cell lines, OCI-LY1, OCI-LY18 and Pfeiffer. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.